New data show treatment with etesevimab (JS016) and bamlanivimab together reduced risk of COVID-19 hospitalizations and death by 70 percent
Trial met primary endpoint and key secondary endpoints with high statistical significance Results from more than 1,000 high-risk patients were consistent with previous data In November, Lilly submitted a EUA request to the FDA for…